Claims for Patent: 8,178,519

Summary for Patent: 8,178,519

Title:	Pharmaceutical manufacturing process for heat sterilized glucocorticoid suspensions
Abstract:	The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.
Inventor(s):	Miller; John (Cheshire, GB), Ronald; Paul (Cheshire, GB), Ashley; Adrian (Cheshire, GB), Lamb; Paul (Cheshire, GB), MacDonald; Donald (Cheshire, GB), Oliver; Martin (Cheshire, GB), Pollard; Matthew (Cheshire, GB)
Assignee:	Norton Healthcare Limited (London, GB)
Application Number:	11/667,872
Patent Claims:	1. A method for preparing a sterile suspension of a glucocorticosteroid comprising the following steps: (i) heating a glucocorticosteroid suspension comprising a glucocorticosteroid, water and a surfactant in a mixing vessel to sterilize the glucocorticosteroid suspension, (ii) re-circulating the glucocorticosteroid suspension via a homogenizer before, during and/or after step (i), and subsequently (iii) mixing the glucocorticosteroid suspension with sterile water or a sterile excipient liquid comprising water and one or more pharmaceutically acceptable excipients; wherein the heating is carried out for at least 2 minutes. 2. A method as claimed in claim 1, wherein the sterile water or sterile excipient liquid is prepared by passing water or an excipient liquid through a sterilizing grade filter. 3. A method as claimed in claim 1, wherein the sterile excipient liquid is used and the one or more pharmaceutically acceptable excipients comprises a surfactant. 4. A method as claimed in claim 1, wherein the sterile excipient liquid is used and the one or more pharmaceutically acceptable excipients comprises at least one of a buffer, a salt, a wetting agent, a stabilizing agent and an isotonic agent. 5. A method as claimed in claim 1, wherein the re-circulating in step (ii) occurs during the heating in step (i). 6. A method as claimed in claim 1, wherein the concentration of the glucocorticosteroid in the glucocorticosteroid suspension is from about 15 to about 300 mg/ml. 7. A method as claimed in claim 1, wherein at least 50% of the glucocorticosteroid in the glucocorticosteroid suspension is in the form of a suspension during heating. 8. A method as claim in 7, wherein at least 60% of the glucocorticosteroid in the glucocorticosteroid suspension is in the form of a suspension during heating. 9. A method as claimed in claim 1, wherein the glucocorticosteroid is selected from the group consisting of at least one of beclomethasone, budesonide, ciclesonide, cortivazol, deflazacort, flumethasone, flunisolide, fluocinolone, fluticasone, mometasone, refleponide, tipredane and triamcinolone. 10. A method as claimed in claim 8, wherein the glucocorticosteroid is beclomethasone or budesonide. 11. A method as claimed in claim 3, wherein the concentration of the surfactant in the glucocorticosteroid suspension is from about 0.2 to about 300 mg/ml. 12. A method as claimed in claim 1, wherein heating is carried out at a temperature of from about 101.degree. C. to about 145.degree. C. 13. A method as claimed in claim 12, wherein heating is carried out at a temperature of from about 122.degree. C. to about 138.degree. C. 14. A method as claimed in claim 1, wherein heating is carried out for about 2 to about 180 mins. 15. A method as claimed in claim 14, wherein heating is carried out for at least about 30 mins. 16. A method as claimed in claim 1, wherein the homogenizer is an in-line homogenizer or a high-pressure homogenizer. 17. A method as claimed in claim 1, wherein, in step (iii), the sterile excipient liquid is used and the glucocorticosteroid suspension is diluted with the sterile excipient liquid to a pharmaceutically suitable concentration. 18. A method as claimed in claim 1 further comprising, subsequent to step (iii), packaging the sterile suspension of a glucocorticosteroid. 19. A method as claimed in claim 18, wherein the sterile suspension of a glucocorticosteroid is packaged by a blow-fill-seal (BFS) machine.

Details for Patent 8,178,519

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2024-11-16